ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these
ScripThe ultra-rare disease specialist Ultragenyx is approaching several important catalysts this year, including US Food and Drug Administration action on UX111 – the firm’s first gene therapy, which targ
ScripThird Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut
ScripKura Oncology and Kyowa Kirin plan to pursue US Food and Drug Administration approval based on positive Phase II topline results for ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemi